OMNY Health, Scipher Medicine partner to advance precision immunology
OMNY Health and Scipher Medicine are partnering to advance precision medicine efforts for immunology.
This collaboration marks a significant leap forward in the fight against autoimmune diseases, integrating transcriptomic data from Scipher Medicine with OMNY Health's EHR network that reaches more than 80 million patients, the companies said.
OMNY Health’s network includes data from nearly 250,000 patients with rheumatoid arthritis, covering key metrics such as functional status, lab values (ESR, CRP), joint counts, CDAI and DAS28, which enables comprehensive tracking of patient outcomes and disease progression.
This partnership is intended to unlock information for researchers and drug developers. By combining the detailed clinical data within OMNY Health's network with the rich genomic insights from PrismRA, a personalized blood test for rheumatoid arthritis, researchers may gain a holistic view of the patient journey. This deeper understanding will fuel the development of more targeted therapies and improve overall patient outcomes. Scipher Medicine has tested over 40,000 rheumatoid arthritis patients using PrismRA, which includes information on treatment response and is the only approved classifier by CMS in the United States.
[Read more: Survey: Patients value personalized medicine]
“At OMNY Health, we are steadfast in our belief that highly targeted therapies and treatments for disease are the key to improving healthcare outcomes,” said Mitesh Rao, founder and CEO of OMNY Health. “Nearly 50 million Americans suffer from autoimmune diseases, and their patient experiences hold valuable insights that, if extracted, could help drive advancements in precision medicine.”
“We recognized the significant role that clinico-transcriptomic data plays in both treatment decisions and bringing precision medicine to patients,” said Reginald Seeto, president and CEO of Scipher Medicine. “Patients deserve clarity and personalized evidence-based answers when navigating individual treatment options. By partnering with OMNY Health, we will enable clinicians and researchers to make data-driven decisions that ultimately reduce the risk to patients.”
In addition, OMNY Health’s partners within life sciences gain access to the valuable clinico-transcriptomic datasets of Scipher Medicine’s PrismRA-tested patients. Precision medicine is heavily reliant on data, with biomarker-dependent drugs making up 42% of approvals by the FDA. By providing drug developers with diverse, multi-modal datasets like those from OMNY Health, they can more effectively identify new patient groups and expand the availability of precision medicine therapies in the market.
[Read more: Bayer launches unit to develop new precision health consumer products]